Gastro Medical News about Fatty Liver

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Non-alcoholic fatty liver disease from pathogenesis to management: an update
Obesity Reviews, 11/02/09

Musso G et al. – NAFLD entails an increased cardiometabolic and liver–related risk, the latter regarding almost exclusively non–alcoholic steatohepatitis (NASH), the progressive form of NAFLD. Pathogenetic models encompass altered hepatic lipid partitioning and adipokine action, increased oxidative stress, free fatty acid lipotoxicity. On this basis, lifestyle–, drug– or surgically induced weight loss, insulin sensitizers, antioxidants, lipid–lowering drugs have been evaluated in NAFLD/NASH. Most trials are small, of short duration, nonrandomized, without histological end points, thus limiting assessment of long–term safety and efficacy of proposed treatments. All NAFLD patients should be evaluated for their metabolic, cardiovascular and liver–related risk. Liver biopsy remains the gold standard for staging NAFLD, but non–invasive methods are under intense development. Weight loss through lifestyle intervention is the initial approach, because of established efficacy on NAFLD–associated cardiometabolic abnormalities, and to emerging benefits on necroinflammation and overall disease activity in NASH. Bariatric surgery warrants further evaluation before it can be routinely considered in morbidly obese NASH.

<< Previous
A comparison of diagnostic tests for lactose malabsorption -...

Next >>
Use of sorafenib in patients with hepatocellular carcinoma before...

Nonalcoholic fatty liver disease: Quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy
Journal of Digestive Diseases, 10/29/09 Relevance Score: 69%

Synergistic effect of fatty liver and smoking on metabolic syndrome
World Journal of Gastroenterology, 11/17/09 Relevance Score: 68%

Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease
Hepatology, 11/04/09 Relevance Score: 68%

Decreased Liver Fatty Acid delta-6 and delta-5 Desaturase Activity in Obese Patients
Obesity, 11/03/09 Relevance Score: 67%

Prevention of I/R injury in fatty livers by ischemic preconditioning is associated with increased mitochondrial tolerance: the key role of ATPsynthase and mitochondrial permeability transition
Transplant International, 10/22/09 Relevance Score: 67%